Coccidioidomycosis future or investigational therapies: Difference between revisions

Jump to navigation Jump to search
m (Changes made per Mahshid's request)
m (Bot: Removing from Primary care)
 
(One intermediate revision by one other user not shown)
Line 10: Line 10:


{{Reflist|2}}
{{Reflist|2}}
{{WH}}
{{WS}}
[[Category:Pulmonology]]
[[Category:Pulmonology]]
[[Category:Needs content]]
[[Category:Needs content]]
[[Category:Fungal diseases]]
[[Category:Fungal diseases]]
[[Category:Biological weapons]]
[[Category:Biological weapons]]
[[Category:Disease]]
[[Category:Disease]]
{{WH}}
[[Category:Emergency medicine]]
{{WS}}
[[Category:Up-To-Date]]
[[Category:Infectious disease]]

Latest revision as of 21:00, 29 July 2020

Coccidioidomycosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

Coccidioides immitis
Coccidioides posadasii

Differentiating Coccidioidomycosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

CT

MRI

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Coccidioidomycosis future or investigational therapies On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Coccidioidomycosis future or investigational therapies

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Coccidioidomycosis future or investigational therapies

CDC on Coccidioidomycosis future or investigational therapies

Coccidioidomycosis future or investigational therapies in the news

Blogs on Coccidioidomycosis future or investigational therapies

Directions to Hospitals Treating Coccidioidomycosis

Risk calculators and risk factors for Coccidioidomycosis future or investigational therapies

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: ; Vidit Bhargava, M.B.B.S [2]

Overview

The major focus has been the development of a defined, T-cell-reactive, recombinant protein vaccine. Cole GT et al in 2008 described the first genetically engineered, live, attenuated vaccine that protects both BALB/c and C57BL/6 mice against coccidioidomycosis. Two chitinase genes (CTS2 and CTS3) were disrupted to yield the attenuated strain, which was unable to endosporulate and was no longer infectious. Vaccinated survivors mounted an immune response characterized by production of both T-helper-1- and T-helper-2-type cytokines. Histology revealed well-formed granulomas and markedly diminished inflammation. Significantly fewer organisms were observed in the lungs of survivors than in those of nonvaccinated mice. However futher research is needed before we adapt these models to human beings.[1]

References

  1. Xue, J.; Chen, X.; Selby, D.; Hung, CY.; Yu, JJ.; Cole, GT. "A genetically engineered live attenuated vaccine of Coccidioides posadasii protects BALB/c mice against coccidioidomycosis". Infect Immun. 77 (8): 3196–208. doi:10.1128/IAI.00459-09. PMID 19487479.

Template:WH Template:WS